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BACKGROUND  
Alzheimer’s Disease (AD) is a progressive 
neurodegenerative disease generally characterized by loss 
of memory, disorientation, and mood/behavioral changes. 
Advanced cases of AD may also include difficulty 
performing basic motor skills such as speaking and 
walking. There are two types of AD that lead to these 
devastating symptoms. Familial AD has an early onset 
and is linked to deterministic mutations in amyloid 
precursor protein (APP), presenilin-1 (PSEN1), and 
presenilin-2 (PSEN2) genes [16]. On the other hand, 
sporadic AD has a late onset and is associated to both the 
apolipoprotein E (APOE) gene and environmental causes. 
Examples of environmental factors include exposure to 
pollution/asbestos, diet, tobacco usage, and exercise [26]. 
Prolonged neuroinflammation leads to the formation and 
prolonged presence of beta-amyloid plaques and 
neurofibrillary tangles (comprised of 
hyperphosphorylated tau proteins) that prevent normal 
neurological functioning; the two formations are key 
criteria necessary for official diagnosis of both familial 
and sporadic forms of the disease [24,41].  
AD currently has no means of therapeutic intervention 
despite extensive molecular research, emphasizing the 
vast complexity of the disease. As a result, scientists 
expanded their prospects towards other potential 
therapeutic targets, taking large interest in the human 
flora. Though this flora is largely populated by bacteria, 
other organisms like archaea, protozoa, fungi, and viruses 
are also present in several systems of the body. This 
review article will focus on evidence published by various 
researchers that suggests microbial involvement plays a 
large role in the development and progression of AD.  
Beta-Amyloid Plaques 
APP, one of the proteins linked to familial AD, is 
responsible for synaptic stability and neuronal protection 
[9]. Normally, it is processed by α-secretase and γ-
secretase to form soluble APPα [9]. Beta amyloid plaques 
are formed by accumulation of Aß40 and Aß42 peptides 
following aberrant processing of APP by ß- and γ-
secretases [33]. Aß42 specifically is toxic and susceptible 
to aggregation compared to its counterpart, Aß40 [27]. 
Both frequent pathogen colonization and/or failure to 
remove these peptides via exocytosis to form soluble 
oligomers following appropriate use can lead to over-
accumulation between the neuronal spaces [35]. This 
agglomeration leads to the formation of plaques that are 
responsible for deteriorating nigh brain tissue through the 
interception of cell function. Duplications of the protein-
coding APP gene can also result in excessive proliferation 
of APP, leading to Aß build-up [9].  
Conversely, recent research has proposed that Aß 
accumulations display antimicrobial properties, which 
supports the idea of plaque formation occurring as a 
response to microbial colonization. In a study comparing 
Aß activity against twelve microorganisms, Aß was 
reported to thwart further microbial growth [43]. These 
findings suggest amyloid plaques may be present as a 
result of defensive responses against pathogen 
colonization. Further research, however, has not yet been 
published quantifying healthy versus excessive amounts 
of the peptide in question. One of the major hypotheses in 
the development of AD suggests Aß protein to be the 
causative agent of Alzheimer’s with subsequent 
hyperphosphorylation of tau proteins leading to cell loss 
and vascular damage [39]. 
Neurofibrillary Tangles 
Tau, the main component of neurofibrillary tangles, is a 
protein that normally binds tightly to microtubules within 
the brain for functional stabilization [40]. Ordinarily, 
phosphorylated and non-phosphorylated tau proteins are 
present and regulated by tau kinases and phosphatases 
[31]. In the AD-inflicted brain, however, this balance is 
disrupted and the regulatory mechanism is impaired, 
causing tau to detach from their associated microtubules 
and attach to other tau proteins instead. This results in the 
hyperphosphorylation of tau proteins that assemble as 
tangles [41]. As a consequence, operations like axonal 
and dendritic transport are disabled.  
Neuroinflammation 
Cytokines, which are responsible for the regulation of 
immunity and inflammatory responses, have been found 
to have significantly elevated concentrations in the AD 
brain compared to baseline [44]. For this reason, 
increased neuroinflammation, plaques, and tangles are 
thought to work in a cyclic manner regarding brain tissue 
deterioration. Amyloid plaques, neurofibrillary tangles 
and prolonged inflammation lead to tissue damage, but 





neuroinflammation also facilitates further formation of 
these debilitating structures [44].  
Microglial cells are strongly associated with Aß buildup 
and enhanced inflammation of brain tissue. Microglial 
cells are the major cell type regarding immune responses. 
Upon activation, these cells produce cytokines as a 
defensive mechanism against pathogen and tissue damage 
[51]. Unfortunately, microglial cell activity is highly 
associated with neurotoxicity despite its intentionally 
helpful function [6]. When repeatedly stimulated, 
activation of these cells causes loss of ability to 
phagocytose Aß with continued output of cytokines [32], 
leading to swift increases in quantity of Aß present.  
MICROBES 
Microbes, in the eye of the general public, receive a bad 
reputation. In reality, the presence and exposure to an 
array of microbes can heavily improve the efficiency of 
the immune system and help regulate bodily functions 
[45]. The human microbiota is constituted by millions of 
diverse microbes. These microbes reside in nearly all 
regions of the body, but especially large aggregates are 
found in the gastrointestinal (GI) tract, skin, oral cavity, 
and respiratory tract. 
Microbial Gut-Brain Axis 
The gut-brain axis (GBA) is a bidirectional 
communication system between the central (CNS) and 
enteric nervous system (ENS). The CNS encompasses the 
brain and spinal cord; the ENS is a division of the 
autonomic nervous system that detects and maintains the 
physiological conditions of the GI tract and coordinates 
intestinal processes like motility, digestion, and barrier 
defense [17]. The appropriate development of both 
systems is reliant on the optimal balance of intestinal 
microbiota, affecting neurotransmitter expression and 
turnover rates [10]. In eubiosis, this communication 
system relays to the hypothalamic pituitary (HPA) axis, 
which acts as the core stress efferent axis and is 
responsible for coordination of adaptive responses within 
the organism [10]. Moreover, as part of the limbic system, 
the HPA axis is involved with memory and emotional 
response.  
It is known that environmental stressors may activate this 
communication system, but recent research has 
pinpointed evidence of gut microbiota acting as a 
signaling component as well [5]. Study results involving 
communication between the vagal nerve and GI tract have 
found that gut microbes can indirectly stimulate the ENS 
via creation of neurotransmitters, short chain fatty acids, 
and/or bacterial metabolites [7]. These communications 
may also be introduced through bacteria that induce a 
similar effect to host hormones. Naturally, since gut 
microbes hold a large role in the regulation of the GI 
environment, it makes sense that dysbiosis may impede 
fine-tuned processes.  
Gut Microbiota 
The GI tract is home to over 1014 microorganisms that aid 
in metabolic and homeostatic responses such as enzyme 
synthesis, nutrient absorption, and production of short-
chain fatty acids [10]. Though the intestinal flora 
accumulates during infancy and remains relatively 
consistent throughout an individual’s life, patients with 
AD showed decreased richness and diversity of microbes 
in comparison to non-afflicted individuals of the same age 
[49]. Under this principle, it has been established that 
obesity has a complex but major role in the residential 
phyla of the gut. Multiple studies have compared the 
relationship between BMI and present flora to find that 
mid-life increases in BMI are correlated with phyla 
alteration that ultimately leads to greater risk for AD 
development [3,18]. Interestingly, the same studies 
discovered that late life increases of BMI protect against 
the progression of AD [3,18]. A low-power piloted study 
found Actinobacteria to be most abundant in postmortem 
AD brain samples, though this must be implemented on a 
multi-regional level to better understand the universality 
of this finding [52]. Irritable bowel syndrome (IBS) also 
has a strong correlation with the development of dementia 
secondary to hypothesized gut dysbiosis [12]. Both IBS 
and gastroenteritis (a great risk factor for development of 
IBS) have shown to be associated with a multitude of 
parasitic pathogens and their overgrowth.  
There are few GI-involved pathogens specifically 
connected to AD. In a study involving AD association 
with infectious burden from viruses and bacteria, 
Helicobacter pylori was one of five pathogens to 
implement higher levels of serum Aß40 and Aß42, which 
interferes with synaptic function, compared to those 
uninfected [8,19]. It is suggested that H. pylori, which is 
typically responsible for gastritis and peptic ulcers 
through elevation of pH, also alters cognitive efficiency 
through neuroinflammation. Another study exploring the 
effects of H. pylori infection found the pathogen to be 
responsible for hyperphosphorylation of tau proteins 
which are fundamental for neurofibrillary tangles as 
mentioned before [50].  
Though the causative role of dysbiosis needs further 
workup, evaluating the effects of antimicrobial properties 
have supported the idea of pathogen-influenced 
physiological changes. In a study of transgenic AD mice 
raised under germ-free conditions, less cerebral amyloid 
depositions were present in comparison to mice exposed 
to microbes [21]. Intriguingly, antibiotic treatment is 
associated with a decrease in fibril formation and an 
increase in cognitive function [46]. It is important to note 
that antibiotics vary in terms of ability to cross the blood 





brain barrier (BBB) [34]. Rifampicin, a compound with 
penetrative potential, has shown a decrease in Aß toxicity 
and aggregation. A study involving mice has also shown 
broad-spectrum antibiotics to decrease tau 
phosphorylation [47]. Despite these findings, absence of 
microbiota did not equate to complete elimination of 
plaque development. 
Oral Microbiota 
Roughly 700 different microorganisms colonize the 
mouth to make up the oral microbiota [25]. While these 
microbes are responsible for medical issues such as dental 
caries, periodontal disease, and edentulism, they also have 
a strong association with AD [36]. Attachment of 
microcolonies in the form of biofilms, commonly known 
as dental plaques, can result in increased virulence of 
pathogens; buildup of dental plaque is commonly 
resolved by daily brushing of teeth but may reside if 
hygienic practices are not consistent or efficient [28]. 
Unless gingival ulcers are present, the routine brushing of 
teeth poses little to no risk for bacteremia to travel through 
the blood stream and colonize the heart and brain [4,22].  
Pathogens that lead to periodontitis may colonize the oral 
cavity and form toxins that decay the teeth and nearby 
issue, which further increase the probability of spread 
[23,42]. Porphyromonas gingivalis is considered one the 
major infectious agents found in the brain of AD patients 
[15]. P. gingivalis may access the brain upon oral 
infection through several pathways, including monocytes, 
endothelial cells pertaining to the BBB, and/or cranial 
nerves [15]. Upon entering the brain, it is suggested that 
the bacteria are spread via the same mechanism through 
which it invades vascular tissue: it travels through 
connected pathways to reach an abundance of neurons 
[42]. In patients with active chronic periodontitis (CP) 
caused by P. gingivalis, a notable decline in cognition was 
reported in comparison to those demented without CP 
[23]. P. gingivalis infection can work in conjunction with 
genetic factors that pose increased risk of AD 
development, such as apolipoprotein E4 (APOE4) and 
triggering receptors expressed on myeloid cells 
(TREM1/TREM2). With a study involving Apoe-/- mice, 
three different bacterial oral infections were induced [38]. 
Only those infected by P. gingivalis showed infection of 
the brain and activation of complement pathways. A 
similar study with transgenic mice that overexpressed 
mutated human-APP were orally infected by P. 
gingivalis. Upon examination of their brains, cognitive 
function was deemed impaired and there arose an increase 
in deposition of plaques like those in AD patients [42]. 
Gingipains, the major virulence factor produced by P. 
gingivalis, are cysteine proteases made up of lysine-
gingipain (Kgp), arginine-gingipain A (RgpA) and 
arginine-gingipain B (RgpB) [30]. Gingipains suppress 
interleukin-2 (IL-2) secretion, which is an extremely 
important humoral immune response to invasion [37]. 
This ultimately leads an inflammatory cascade to the 
brain that modifies the clonal formation of T helper 17 
(Th17) cells, resulting in an immune cell population 
imbalance that works in favor of P. gingivalis [37]. These 
cysteine proteases may induce proteolysis of tau proteins 
to which the host attempts to compensate for, increasing 
production rates to maintain homeostasis [40]. With 
APOE4, the apolipoprotein itself is a large target for 
gingipain proteolysis which may result in the generation 
of neurotoxic fragments [30]. TREM2, which normally 
regulates inflammatory responses, serves as a phagocytic 
receptor for bacteria [16]. TREM1, with structural 
homology to TREM2, has also been linked with AD as P. 
gingivalis has proved to increase expression of the allele 
that is already a target for gingipain proteolysis (by Rgp) 
and degradation (by Kgp) [16]. These actions have a 
correlation with neuroinflammation following infection.  
A study evaluating herpes virus simplex 1 (HSV 1) was 
also linked to increased risk for the development of AD. 
Multiple logistic regressions found that APOE4 
frequency was much higher in those affected by both 
HSV1 and AD, signifying a strong risk factor when paired 
[8]. Though recurrence of HSV1 symptoms lessen with 
age, the connection between the virus and APOE4 may 
determine the extent of damage. Both the virus and 
apolipoproteins bind to heparin sulphate proteoglycans in 
cell plasma membranes which affects the number of cells 
infected. The mechanism of HSV1 as a vector, however, 
must be further investigated. 
Respiratory Microbiota 
The respiratory tract, with lower components previously 
thought to be sterile, actually harbors a large array of 
microorganisms that aid in resistance of pathogen 
colonization [13,14]. Acutely responsible for community-
acquired pneumonia and asthmatic bronchitis, recent 
studies have pinpointed Chlamydia pneumoniae infection 
as a potential trigger for AD. Mice inoculated with C. 
pneumoniae demonstrated Aß42 deposits that steadily 
increased in number over the course of 1-3 months [29]. 
This microorganism has demonstrated elicitation of 
extreme inflammatory responses, which are characteristic 
in the AD brain [20]. With higher bacterial burden 
showed extremely high levels of tissue and cellular 
damage within the brains of AD patients. Data also 
suggests the load has a positive correlation with the 
presence of the APOE4 allele, though the role in 
neuropathogenesis is unclear [20].  
Mycobiota 
Fungal microbial flora makes up less than 1% of the 
human flora [48]. Fungi is most typically found either on 





the skin or within the mucosal membranes of the human 
body. However, recent examination of brain tissue has 
unveiled the presence of fungal DNA and proteins in 
patients with AD [2] as well as fungal residues within 
neurons [37], all of which were not observed in control 
patients. Cerebrospinal fluid (CSF) may tell a lot about 
fungal contribution to AD. Within the CSF of those 
positive for Alzheimer’s, chitin (the major component of 
fungal cell walls) has been identified [11].  
Candida albicans is one of the major fungal organisms 
found in CSF. Candidemia, caused by C. albicans, proves 
the ability of fungi to cross the BBB via mucosal 
colonization [51]. Recent studies have shown C. albicans 
to increase activation of both interleukins and tumor 
necrosis factors, indicating the fungi can cause extensive 
neuroinflammation upon seepage into the BBB [51]. The 
presence of the fungus within the BBB additionally leads 
to enhancement of the development of Aß plaques due to 
their antimicrobial properties [43,51]. It is therefore 
plausible that formation occurs as a defensive response 
against C. albicans. Another cytoplasmic experiment has 
found AD brain tissue to have abnormally high amounts 
of tau when fungal infection has come into the equation, 
though this finding has not been verified through separate 
studies [37]. 
CONCLUSION 
Though microbes are not considered to be the sole drivers 
in development and progress, there is paramount evidence 
supporting the association between dysbiosis and AD. 
Further research to understand exact mechanisms of 
pathogenesis and roles of individual microorganisms is 
imperative if there is any hope for a treatment or cure for 
AD. Although fungi has remarkable associations with 
AD, significance of the results are limited due to low 
quantity of animal studies. This is especially important 
considering the conceptual confliction with the amyloid 
cascade hypothesis. 
It is known that genes like TREM1, TREM2, and 
especially APOE4 have a crucial role in the development 
of amyloid plaques and neurofibrillary tangles. It would 
appear that the presence of the APOE4 allele supports or 
promotes pathogenesis of several harmful microbes [20]. 
These genetic risks impose facilitation of pathogens 
through the BBB where they may induce 
neuroinflammation and/or development of neurologically 
debilitating structures.  
Given limited understanding of AD, there is no 
guaranteed safety from the disease. However, there are 
several preventative measures indicated when 
considering aforementioned findings. For example, those 
with a higher genetic predisposition to AD yield better 
protection when they complete their full antibiotic course 
prescribed for common infections they may come across 
in their lifetime. Whether the antimicrobial treatment is in 
place for upper respiratory or oral infections, finishing the 
full course of these medications minimizes the risk of 
bacterial allocation and/or resistance by limiting the 
activation of microglia that leads to inflammation [6]. 
Proper oral hygiene may also serve as a pertinent step in 
prevention of oral-associated infections. Daily removal of 
plaques prevents aggregation of P. gingivalis bacteria 
responsible for gum disease [28]. Regarding the gut 
microbiome, weight maintenance, health-conscious diet 
and the consumption of probiotics help prevent the 
likelihood of gut dysbiosis by maintaining microbial 
diversity [1]. Since genetic changes may not be plausible, 
being proactively well-rounded in maintenance of one’s 
health is thought to be a supportive factor in keeping 
distance from AD. 
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